BioSpace3d
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
“These results, alongside the OLYMPIA 2 trial data, formed the basis of nemolizumab’s recent U.S. Food and Drug Administration approval for the treatment of adults with prurigo nodularis. They ...
BioSpace3d
Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor ...
BioSpace3d
Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage ...
BioSpace3d
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare ...
BioSpace3d
Zai Lab Announces the Inclusion of AUGTYRO® (repotrectinib) for ROS1+ NSCLC and Other Updates in China’s National Reimbursement Drug List
“The NRDL inclusion of AUGTYRO significantly expands access to patients living with ROS1+ NSCLC in China to a new treatment option with promising durability. We look forward to launching AUGTYRO by ...
BioSpace3d
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare ...
BioSpace3d
Radiopharm Achieves Nasdaq Listing of American Depositary Shares
Trading under ticker symbol RADX Complements existing US shareholders (currently holding 21% of Radiopharm) No associated capital raising Modest admin & financial compliance overheads SYDNEY, Nov. 27, ...
BioSpace3d
WORK Medical Technology Group LTD’s Subsidiary, Hangzhou Shanyou, Showcases Products at MEDICA Trade Fair 2024
Hangzhou, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, today announced that its ...
BioSpace3d
Prenetics Announces Third Quarter 2024 Financial Results
Successfully launched IM8health.com on November 18, 2024 and shipping to 31 countries and regions. Initial customer response has been very positive. Completed the acquisition of Europa Sports Partners ...
BioSpace3d
SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers
- Preselection Method for Cancers Responding to SLS009: High Efficacy of SLS009 Observed in 67% of ASXL1 Mutated Solid Cancers vs 0% in Non-ASXL1 Mutated Cancers – - ASXL1 Mutations Predictably ...
BioSpace3d
Innovent Announces First-Time Inclusion of SINTBILO® and New Indication for Olverembatinib in China’s National Reimbursement Drug List
SAN FRANCISCO and SUZHOU, China, Nov. 27, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
BioSpace3d
Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company”, “Kane Biotech” or “Kane”) announces ...